Pharmaceutical

MaxCyte and Kamau Therapeutics sign platform license agreement

MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.

Sep 18, 2024 - 04:00
MaxCyte and Kamau Therapeutics sign platform license agreement
MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.
Read the original article

Tags:

Previous Article

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

Next Article

Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Intercept winds down NASH programme after FDA pulls plug on Ocaliva

Intercept winds down NASH programme after FDA pulls plu...

Jun 23, 2023

STAT+: Apellis safety probe of eye disease drug identifies injection needle as possible cause of severe side effect

STAT+: Apellis safety probe of eye disease drug identif...

Aug 23, 2023

STAT+: Pharmalittle: Patients brace for insurance decisions on weight loss drugs; Indian authorities find multiple problems at pharma plants

STAT+: Pharmalittle: Patients brace for insurance decis...

Aug 3, 2023